Immunovant, Inc.
Company Stats
- Market Cap
- $7.0B
- as of Sep 30, 2026
- Shares Outstanding
- 206.6M
- Free Float
- 40.0%
Income Statement
- Net Income
- -$505.6M
Cash Flow
- Free Cash Flow
- -$407.3M
- FCF Yield
- -5.8%
- Owner FCF Yield
- -6.6%
Balance Sheet
- Cash & Equivalents
- $902.1M
Returns & Capital
- SBC, 3Y Avg
- $48.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2026 | — | -$407.3M | — |
| FY2025 | — | -$376.6M | — |
| FY2024 | — | -$214.6M | — |
| FY2023 | — | -$188.4M | — |
| FY2022 | — | -$106.4M | — |
Annual filing data through FY ended March 31, 2026; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges